Once singled out as the “most winning” stock-picker in the investment newsletter industry, Ernie Tremblay has more than 25 years of experience in following and analyzing the latest developments in health, medicine, and related technologies.
But his background isn’t in stock-picking at all.
As a health editor and writer, Ernie has contributed to more than 100 publications on topics like diabetes, Alzheimer’s disease, arthritis, dermatology, and groundbreaking medical therapies, for top publishers such as Prentice Hall, Harper Collins, and others. Over the decades, Ernie has gained “insider” access to some of the world’s top medical professionals, including Nobel-caliber doctors like Yale’s Karel Liem, Columbia’s George Gaylord Simpson, and Harvard’s William S. Beck.
Ernie understands the FDA approval process, as well as the “hard science” behind new, experimental drugs and the market demand for them – and has a comprehensive grasp of the complex dynamics that determine whether a new drug will be a breakthrough winner, or just another casualty of the FDA approval process.
So, when Ernie turned his attention to the biotech investing world, he discovered what everybody was getting wrong – What every other “expert” analyst didn’t know.
It’s the simplest question on earth: Does the science behind the drug work?
When you can master that one simple question (and no one else can), you can get extremely rich. Ernie proved that almost right away.
In 2012, after years of calibration and testing, Ernie started publishing his recommendations exclusively for Money Map members, using a proprietary Three-Phase System that identifies the next “blockbuster” drugs and determines whether upcoming regulatory events will make a stock rocket skyward or plunge in the opposite direction. Most remarkably, he maintains a calendar that shows when the gains will come, down to the day.
His very first recommendation was a “buy” on a small-cap biotech called Aegerion Pharmaceuticals Inc. (AEGR). The company was developing a new orphan drug to treat a rare, fatal blood disease in young adults. Ernie was convinced it was a winner.
In October 2012, when the stock was $17/share, he wrote to members:
“[I] put the potential share price of this company at just shy of $72 per share. Based on the current share price – that represents a potential first-year gain of over 360%.”
As it turned out, the stock delivered a 346% total return for members in just eight months – four months ahead of schedule.
Today Ernie still uses this very same system to track the best profit opportunities for his Biotech Insider Alert members. He also contributes to Money Morning as the biotech investing specialist.